製品番号: HY-P1033

[Pyr1]-Apelin-13

Name: [Pyr1]-Apelin-13
Brand: MedChemExpress
SKU: HY-P1033
Price: 110.00 USD
Availability: InStock
Rating: 5 (6 reviews)

(別名: [pGlu1]-Apelin-13; (Pyr1)-アペリン-13)

6 Cited Publications

カスタマーレビュー

Based on 6 publication(s) in Google Scholar

[Pyr1]-Apelin-13 is a highly potent, selective endogenous apelin receptor (APJ) agonist.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度 : 99.64%
CAS 番号: 217082-60-5
分子式: C₆₉H₁₀₈N₂₂O₁₆S
分子量:1533.80

保管条件:

Sealed storage, away from moisture.

Powder -80°C, 2 years , -20°C, 1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

[Pyr1]-Apelin-13 構造式

CAS 番号: 217082-60-5

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- Cellular Effect
- 体外実験
- 体内実験
化学情報
Publications (6)
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

[Pyr1]-Apelin-13 is a highly potent, selective endogenous apelin receptor (APJ) agonist.

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	EC₅₀	0.42 nM Compound: 1, Pyr-apelin-13	Agonist activity at APJ receptor (unknown origin) expressed in CHO cells co-expressing with Calphaq16 assessed as calcium mobilization Agonist activity at APJ receptor (unknown origin) expressed in CHO cells co-expressing with Calphaq16 assessed as calcium mobilization	[PMID: 24755525]
CHO	EC₅₀	0.002 μM Compound: Pyr-Apelin-13	Agonist activity at human APJ receptor stably expressed in CHO cells co-expressing Galphaq16 assessed as increase in intracellular calcium mobilization measured at 1 sec intervals for 90 secs by calcium 5 dye based FLIPR assay Agonist activity at human APJ receptor stably expressed in CHO cells co-expressing Galphaq16 assessed as increase in intracellular calcium mobilization measured at 1 sec intervals for 90 secs by calcium 5 dye based FLIPR assay	[PMID: 31948845]
CHO	EC₅₀	0.0003 μM Compound: Pyr-Apelin-13	Agonist activity at human APJ receptor stably expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation measured after 30 mins by Eu-cAMP tracer based TR-FRET assay Agonist activity at human APJ receptor stably expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation measured after 30 mins by Eu-cAMP tracer based TR-FRET assay	[PMID: 31948845]
CHO	EC₅₀	0.3 nM Compound: Pyr-Apelin-13	Agonist activity at human APJ receptor stably expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation measured after 30 mins by Eu-cAMP tracer based TR-FRET assay Agonist activity at human APJ receptor stably expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation measured after 30 mins by Eu-cAMP tracer based TR-FRET assay	[PMID: 31948845]
CHO-K1	EC₅₀	0.001 μM Compound: Pyr-Apelin-13	Agonist activity at human APJ receptor stably expressed in CHOK1 cells assessed as induction of beta-arrestin 2 recruitment incubated for 90 mins by PathHunter assay Agonist activity at human APJ receptor stably expressed in CHOK1 cells assessed as induction of beta-arrestin 2 recruitment incubated for 90 mins by PathHunter assay	[PMID: 31948845]
HEK293	EC₅₀	12.2 pM Compound: [pyr1]-apelin-13	Agonist activity at APJ receptor in HEK293 cells assessed as inhibition of forskolin-induced cAMP level incubated for 5 mins prior to forskolin challenge measured after 30 mins by TR-FRET assay Agonist activity at APJ receptor in HEK293 cells assessed as inhibition of forskolin-induced cAMP level incubated for 5 mins prior to forskolin challenge measured after 30 mins by TR-FRET assay	[PMID: 25241924]
HEK293	EC₅₀	0.84 nM Compound: Ape13	Agonist activity at human APJ receptor expressed in HEK293 cells assessed as induction of Galphai1 subunit dissociation incubated for 5 mins by BRET assay Agonist activity at human APJ receptor expressed in HEK293 cells assessed as induction of Galphai1 subunit dissociation incubated for 5 mins by BRET assay	[PMID: 25668242]
HEK293	EC₅₀	1.4 nM Compound: Ape13	Agonist activity at human APJ receptor expressed in HEK293 cells assessed as inhibition of forskolin-induced intracellular cAMP production incubated for 30 mins by TR-FRET assay Agonist activity at human APJ receptor expressed in HEK293 cells assessed as inhibition of forskolin-induced intracellular cAMP production incubated for 30 mins by TR-FRET assay	[PMID: 25668242]
HEK293	EC₅₀	26 nM Compound: Ape13	Agonist activity at human APJ receptor expressed in HEK293 cells assessed as induction of beta-arrestin-1 recruitment subunit dissociation incubated for 30 mins by BRET assay Agonist activity at human APJ receptor expressed in HEK293 cells assessed as induction of beta-arrestin-1 recruitment subunit dissociation incubated for 30 mins by BRET assay	[PMID: 25668242]
HEK293	EC₅₀	29 nM Compound: Ape13	Agonist activity at human APJ receptor expressed in HEK293 cells assessed as induction of beta-arrestin-2 recruitment subunit dissociation incubated for 30 mins by BRET assay Agonist activity at human APJ receptor expressed in HEK293 cells assessed as induction of beta-arrestin-2 recruitment subunit dissociation incubated for 30 mins by BRET assay	[PMID: 25668242]
HEK293	EC₅₀	5.9 nM Compound: Ape13	Agonist activity at human APJ receptor expressed in HEK293 cells assessed as induction of GalphaoA subunit dissociation incubated for 5 mins by BRET assay Agonist activity at human APJ receptor expressed in HEK293 cells assessed as induction of GalphaoA subunit dissociation incubated for 5 mins by BRET assay	[PMID: 25668242]
HEK293	IC₅₀	1.2 nM Compound: Ape13	Displacement of [125I]apelin-13[Glp65,Nle75,Tyr77] from YFP epitope-tagged human APJ receptor expressed in HEK293 cell membranes incubated for 1 hr by gamma counting method Displacement of [125I]apelin-13[Glp65,Nle75,Tyr77] from YFP epitope-tagged human APJ receptor expressed in HEK293 cell membranes incubated for 1 hr by gamma counting method	[PMID: 25668242]
HEK293	EC₅₀	1.1 nM Compound: Ape13	Activity at human APJ receptor expressed in HEK293 cells assessed as dissociation of Galphai1 from Gbetagamma subunit after 5 mins by BRET assay Activity at human APJ receptor expressed in HEK293 cells assessed as dissociation of Galphai1 from Gbetagamma subunit after 5 mins by BRET assay	[PMID: 29461833]
HEK293	EC₅₀	24 nM Compound: Ape13	Induction of human HA-tagged APJ receptor internalization expressed in HEK293 cells after 30 mins by ELISA Induction of human HA-tagged APJ receptor internalization expressed in HEK293 cells after 30 mins by ELISA	[PMID: 29461833]
HEK293	EC₅₀	60 nM Compound: Ape13	Activity at GFP10-tagged human APJ receptor expressed in HEK293 cells assessed as induction of RlucII-tagged beta-arrestin-2 recruitment after 30 mins by BRET assay Activity at GFP10-tagged human APJ receptor expressed in HEK293 cells assessed as induction of RlucII-tagged beta-arrestin-2 recruitment after 30 mins by BRET assay	[PMID: 29461833]
HEK293	EC₅₀	0.047 nM Compound: 1; (Pyr1)apelin-13	Agonist activity at human APJ-R expressed in HEK293 cells assessed as inhibition of forskolin- stimulated cAMP accumulation incubated for 30 mins by HTRF assay Agonist activity at human APJ-R expressed in HEK293 cells assessed as inhibition of forskolin- stimulated cAMP accumulation incubated for 30 mins by HTRF assay	[PMID: 31724863]
HEK293	EC₅₀	0.062 nM Compound: 1; (Pyr1)apelin-13	Agonist activity at rat APJ-R expressed in HEK293 cells assessed as inhibition of forskolin- stimulated cAMP accumulation incubated for 30 mins by HTRF assay Agonist activity at rat APJ-R expressed in HEK293 cells assessed as inhibition of forskolin- stimulated cAMP accumulation incubated for 30 mins by HTRF assay	[PMID: 31724863]

体外実験

[Pyr1]-apelin-13 encapsulation in lipoPEG particles (lipoPEG-PA13) results in sustained and extended drug release under physiological conditions^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

[Pyr1]-apelin-13 nanocarriers in a mouse model of pressure-overload induced heart failure demonstrate a sustainable long-term effect of [Pyr1]-apelin-13 in preventing cardiac dysfunction^[1]. [Pyr1] apelin-13 (1, 5 μg) improves locomotor activity and reduces pain symptoms, cavity size and caspase-3 levels in rats. [Pyr1] apelin-13 (1, 5 μg) significantly increases thermal paw withdrawal latency. [Pyr1] apelin-13 in 5 μg dose also produces significant attenuation in paw withdrawal threshold compared to SCI animals from the second week post SCI^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

化学情報

CAS 番号 217082-60-5
性状 Solid
分子量 1533.80
分子式 C₆₉H₁₀₈N₂₂O₁₆S
Color White to off-white
別名

[pGlu1]-Apelin-13; (Pyr1)-アペリン-13
配列

{Glp}-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Phe
シーケンスの短縮

{Glp}-RPRLSHKGPMPF
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (6)

All IFCell Proliferation/Viability AssayWB2D/3D Cell Culture and DifferentiationCell Migration/Invasion Assay

Sort by:

Journal Impact Factor

J Transl Med

Apelin-13 attenuates optic nerve damage in glaucomatous mice by regulating glucose metabolism. [Abstract]

2025 Feb 18;23(1):200. PMID: 39966959

[Pyr1]-Apelin-13 purchased from MedChemExpress. Usage Cited in: J Transl Med. 2025 Feb 18;23(1):200. [Abstract]

The number of RGCs was significantly lesser in the PECE group than in the control group. Moreover, the number of surviving RGCs was significantly greater in the Apelin-13 (10 µg/eye) group than in the PECE group.

[Pyr1]-Apelin-13 purchased from MedChemExpress. Usage Cited in: J Transl Med. 2025 Feb 18;23(1):200. [Abstract]

The ratios of p-PI3K/PI3K and p-Akt/Akt in the retina of the PECE group were decreased, while those in the Apelin-13 (10 µg/eye) group returned to normal.

[Pyr1]-Apelin-13 purchased from MedChemExpress. Usage Cited in: J Transl Med. 2025 Feb 18;23(1):200. [Abstract]

Tube formation experiment. The mBMECs in matrix gels were treated with vehicle or Apln13 (100 ng/mL) in reduced growth media (2% FBS) or cultured in normal growth media (5% FBS) for 4 h. Representative images of tubular-like structures.

[Pyr1]-Apelin-13 purchased from MedChemExpress. Usage Cited in: J Transl Med. 2025 Feb 18;23(1):200. [Abstract]

In vitro scratch assay in mBMEC cultures in reduced growth media (2% FBS) with vehicle or Apln13 treatment (100 ng/mL). Normal growth media (5% FBS) was used as a positive control. Scratch area closure was assessed after 0, 6, 12, 24, and 30 h.
Int Immunopharmacol

Apelin-13 alleviated ischemia reperfusion injury via KLF2/NF-κB signaling pathway after kidney transplantation. [Abstract]

2026 Jan 1;168(Pt 1):115802. PMID: 41223609
iScience

Single-cell transcriptomic analyses reveal angiogenic vascular responses to chronic cerebral hypoperfusion. [Abstract]

2026 Mar 11;29(4):115331. PMID: 41907427

[Pyr1]-Apelin-13 purchased from MedChemExpress. Usage Cited in: iScience. 2026 Mar 11;29(4):115331. [Abstract]

Proliferation analysis under different concentrations of Apln13 treatment (0, 10, 100, and 500 ng/mL) for 20 h.
SSRN

2026 Jun 17.
bioRxiv

2026 Mar 30:2026.03.26.714294. PMID: 41958979
Research Square Print

2023 Jan 23.

溶剤 & 溶解度

体外:

H₂O : 100 mg/mL (65.20 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

0.6520 mL

3.2599 mL

6.5198 mL

5 mM

0.1304 mL

0.6520 mL

1.3040 mL

10 mM

0.0652 mL

0.3260 mL

0.6520 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 100 mg/mL (65.20 mM); Clear solution; Need ultrasonic

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (276 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Serpooshan V, et al. [Pyr1]-Apelin-13 delivery via nano-liposomal encapsulation attenuates pressure overload-induced cardiac dysfunction. Biomaterials. 2015 Jan;37:289-98. [Content Brief]

[2]. Hajimashhadi Z, et al. Chronic administration of [Pyr1] apelin-13 attenuates neuropathic pain after compression spinal cord injury in rats. Neuropeptides. 2017 Feb;61:15-22. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O	1 mM	0.6520 mL	3.2599 mL	6.5198 mL	16.2994 mL
	5 mM	0.1304 mL	0.6520 mL	1.3040 mL	3.2599 mL
	10 mM	0.0652 mL	0.3260 mL	0.6520 mL	1.6299 mL
	15 mM	0.0435 mL	0.2173 mL	0.4347 mL	1.0866 mL
	20 mM	0.0326 mL	0.1630 mL	0.3260 mL	0.8150 mL
	25 mM	0.0261 mL	0.1304 mL	0.2608 mL	0.6520 mL
	30 mM	0.0217 mL	0.1087 mL	0.2173 mL	0.5433 mL
	40 mM	0.0163 mL	0.0815 mL	0.1630 mL	0.4075 mL
	50 mM	0.0130 mL	0.0652 mL	0.1304 mL	0.3260 mL
	60 mM	0.0109 mL	0.0543 mL	0.1087 mL	0.2717 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Bioz

Keywords

[Pyr1]-Apelin-13

6 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

[Pyr1]-Apelin-13

MedChemExpress（MCE）の使用を引用している文献 [Pyr1]-Apelin-13

生物活性

製品説明

Cellular Effect

体外実験

体内実験

化学情報

Publications (6)

溶剤 & 溶解度

体外:

体内:

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Bioz

Keywords

最近チェックした製品

[Pyr1]-Apelin-13

MedChemExpress（MCE）の使用を引用している文献 [Pyr1]-Apelin-13

生物活性

製品説明

Cellular Effect

体外実験

体内実験

化学情報

Publications (6)

溶剤 & 溶解度

体外:

体内:

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

[Pyr1]-Apelin-13 関連分類

HY-P1033 関連分類

Bioz

Keywords

最近チェックした製品